ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2771 • 2019 ACR/ARP Annual Meeting

    A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate

    Amee Sonigra 1, Hendrik Nel 2, Nishta Ramnoruth 2, Meghna Talekar 2, Joanne Tesiram 3, Frederik Stuurman 4, Lavinia Proctor 5, Helen Roberts 6, Robin Thurmond 7, Phillip Vecchio 3, Ian Gourley 8, Mark Rigby 9, Nathan Felix 10, Stephane Becart 11, Kim Campbell 12 and Ranjeny Thomas2, 1Princess Alexandra Hospital, Woolloongabba, Queensland, Australia, 2University of Queensland, Woolloongabba, Australia, 3Princess Alexandra Hospital, Woolloongabba, Australia, 4Centre for Human Drug Research, Leiden, Netherlands, 5Dendright, Woolloongabba, Australia, 6Dendright, Woolloongabba, Queensland, Australia, 7Janssen Research & Development, La Jolla, CA, 8Janssen Research & Development, Springhouse, 9Janssen Research & Development, La Jolla, 10Janssen R&D, Spring House, PA, 11Janssen R&D, La Jolla, CA, 12Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Antigen-specific immunological tolerance strategies leverage the natural process of antigen presentation by dendritic cells (DCs) to regulate pathogenic T cells and B cells. We…
  • Abstract Number: 2772 • 2019 ACR/ARP Annual Meeting

    Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet

    francesca cedola1, Roxana Coras 2, Marta Fernandez-Bustamante 3, Meritxell Agusti-Perez 3, Maram Al-Harthi 3, Susan Lee 3, Abha Singh 3, Choi Soo 3, Kathy Nguyen 3, Oswald Quehenberger 3, Tatyana Shekhtman 3, Shahrokh Golshan 3 and Monica Guma 4, 1University of California San Diego, Rome, Italy, 2. Department of Medicine, School of Medicine. University of California, San Diego, 3University of California San Diego, san diego, 4Department of Medicine, School of Medicine. University of California San Diego, La Jolla, United States

    Background/Purpose: RA patients often inquire about dietary interventions to improve disease control, as they perceive quick changes in pain and/or swelling after consumption of certain…
  • Abstract Number: 2773 • 2019 ACR/ARP Annual Meeting

    Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier

    Asmir Vodencarevic 1, David Simon 2, Fabian Hartmann 2, Michaela Reiser 2, Axel Hueber 2, Koray Tascilar 3, Arnd Kleyer 4, Marcus Zimmermann-Rittereiser 1 and Georg Schett5, 1Siemens Healthcare GmbH, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, 4Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 5Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Tapering or stopping conventional and biologic DMARDs in patients with rheumatoid arthritis (RA) in stable  remission may be feasible in a subset of patients…
  • Abstract Number: 2774 • 2019 ACR/ARP Annual Meeting

    Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort

    Félicie Costantino 1, Philippe Aegerter 2, Anna Moltó 3, Georg Schett 4, Maxime Breban 5 and Maria-Antonietta D'Agostino6, 1UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, 2Public Health Department - GIRCI IdF - INSERM/Versailles-Saint Quentin University, France, Versailles, France, 3Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 4Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, 5UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, 6UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne Billancourt, France

    Background/Purpose: The course of axial spondyloarthritis (SpA) is heterogeneous and remains to be better defined. DESIR is a longitudinal French cohort of early undifferentiated axial…
  • Abstract Number: 2775 • 2019 ACR/ARP Annual Meeting

    Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort

    Marion Pons 1, Nathalie Costedoat-Chalumeau 2, Karine Briot 3, Philippe Goupille 4, Christian Roux 5, Maxime Dougados 6 and Anna Moltó5, 1Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, 2Cochin University Hospital, Paris, France, 3Rheumatology department, Cochin Hospital, Paris, France, Paris, Ile-de-France, France, 4Tours University-Hospital, Tours, France, Tours, France, 5Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 6Cochin Hospital, Paris, France

    Background/Purpose: Only scarce data is available on regarding pregnancy rates and pregnancy outcomes in early axial spondyloarthritis (axSpA). The objectives of this study were to…
  • Abstract Number: 2776 • 2019 ACR/ARP Annual Meeting

    5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort

    Marion Pons 1, Sylvie Chevret 2, Karine Briot 1, Maria-Antonietta D’Agostino 3, Christian Roux 4, Maxime Dougados 5 and Anna Moltó4, 1Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, 2INSERM U-1153, CRESS Paris-Sorbonne, Paris, Paris, Ile-de-France, France, 3Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France, 4Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 5Cochin Hospital, Paris, France

    Background/Purpose: Only scarce date is available on the long term treatment effect in a real-life setting (i.e. effectiveness) of TNFi in early axial SpA forms…
  • Abstract Number: 2777 • 2019 ACR/ARP Annual Meeting

    What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts

    Alexandre Sepriano1, Sofia Ramiro 2, Désirée van der Heijde 1, Pierre Hoonhout 3, Anna Moltó 4, Alain Saraux 5, Maxime Dougados 6 and Robert B.M. Landewé 7, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 3ISEG - Lisbon School of Economics and Management, Lisbon, Portugal, 4Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 5CHU de la Cavale-Blanche Brest, Brest, France, 6Cochin Hospital, Paris, France, 7Amsterdam University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Axial spondyloarthritis (axSpA) is a disease with a rather heterogeneous presentation that may be difficult to diagnose. Classification criteria, such as the ASAS criteria,…
  • Abstract Number: 2778 • 2019 ACR/ARP Annual Meeting

    Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)

    Hong Ki Min1, Seung-Ki Kwok 2 and Sang-Heon Lee 1, 1Konkuk university medical center, Seoul, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Background/Purpose: The purpose of the present study was to demonstrate the predicting factors of spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort…
  • Abstract Number: 2779 • 2019 ACR/ARP Annual Meeting

    Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors

    Alexandre Sepriano1, Sofia Ramiro 2, Stephanie Wichuk 3, Praveena Chiowchanwisawakit 4, Terrie MacCosham 3, Joel Paschke 5, Désirée van der Heijde 1, Robert B.M. Landewé 6 and Walter Maksymowych 7, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 3University of Alberta, Edmonton, Canada, 4Mahidol University, Bangkok, Thailand, 5CARE Arthritis, Edmonton, Canada, 6Amsterdam University Medical Center, Amsterdam, Netherlands, 7University of Alberta and CARE Arthritis, Edmonton, Canada

    Background/Purpose: The association between disease activity and spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) has been previously shown in a cohort of patients (pts)…
  • Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting

    Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation

    Celline C. Almeida-Brasil 1, Evelyne Vinet 2, Christian Pineau 2 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…
  • Abstract Number: 2781 • 2019 ACR/ARP Annual Meeting

    Risk of Cardiovascular Disease Associated with the Use of Glucocorticoids in Patients with Incident Systemic Lupus Erytematosus: A Population-based Study

    Lingyi Li1, Hui Xie 2, Eric Sayre 1 and J. Antonio Avina-Zubieta 3, 1Arthritis Research Canada, Vancouver, BC, Canada, 2Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, 3Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk for cardiovascular disease (CVD). SLE itself predisposes patients to accelerated atherosclerosis. In addition, the…
  • Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting

    Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications

    Daniel Li1, Candace Feldman 1, Hongshu Guan 1, Brendan Everett 2, Seoyoung C. Kim 3 and Karen Costenbader 2, 1Brigham and Women's Hospital, Boston, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital and Harvard Medical School, Boston

    Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…
  • Abstract Number: 2783 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous

    Maximlian Konig1, Jessica Li 1 and Michelle Petri 1, 1Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: The antimalarial drug hydroxychloroquine (HCQ) has a primary role in the treatment of systemic lupus erythematous (SLE). Beyond its pleiotropic immunomodulatory effects on TLR…
  • Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting

    Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients

    Melissa E. Munroe1, Carla J. Guthridge 1, Sarah Kleckner 1, Ly Tran 2, Joel Guthridge 3, Debra J. Zack 4, Judith James 3 and Joan T. Merrill 5, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, 3Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Xencor, Inc., San Diego, CA, 5Okalahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…
  • Abstract Number: 2785 • 2019 ACR/ARP Annual Meeting

    Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications

    Sasha Bernatsky1, Rosalind Ramsey-Goldman 2, Murray Urowitz 3, John Hanly 4, Caroline Gordon 5, Michelle Petri 6, Ellen M Ginzler 7, Daniel J Wallace 8, Sang-Cheol Bae 9, Juanita Romero-Diaz 10, MA Dooley 11, Christine Peschken 12, David A Isenberg 13, Anisur Rahman 14, Susan Manzi 15, Soren Jacobsen 16, S Sam Lim 17, Ronald F Van Vollenhoven 18, Ola Nived 19, Diane Kamen 20, Cynthia Aranow 21, Jill Buyon 22, Guillermo Ruiz-Irastorza 23, Ian Bruce 24, Dafna Gladman 25, Paul Fortin 26, Joan T. Merrill 27, Jorge Sanchez-Guerrero 28, Kenneth C Kalunian 29, Kristjan Steinsson 30, Manuel Ramos 31, Asad Zoma 32, Thomas Stoll 33, Munther A Khamashta 34, Murat Inanc 35 and Ann E Clarke 36, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2Northwestern University, Chicago, IL, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, 5University of Birmingham, Birmingham, United Kingdom, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7State University of New York Downstate Medical Center, Brooklyn, NY, 8Cedars-Sinai Medical Centre, Beverly Hills, CA, 9Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 10Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, 11UnC Kidney Centre, Chapel Hill, NC, 12University of Manitoba, Winnipeg, Canada, 13Centre for Rheumatology, London, United Kingdom, 14University College London, London, United Kingdom, 15Allegheny Health Network, Pittsburg, PA, 16Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, 17Emory University, Atlanta, GA, 18Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, 19Lund University, Lund, Sweden, 20Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, 21Feinstein Institute for Medical Research, Manhasset, NY, 22NYU School of Medicine, New York, 23Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, 24University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 25Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 26Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, 27Okalahoma Medical Research Foundation, Oklahoma City, OK, 28Toronto Western Hospital, Toronto, ON, Canada, 29UC San Diego School of Medicine, LaJolla, CA, 30Landspitali, University Hospital, Reykjavik, Iceland, 31Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, 32Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, 33University of Glasgow, Kilbride, Scotland, United Kingdom, 34King's College London School of Medicine, London, United Kingdom, 35Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 36University of Calgary, Calgary, AB, Canada

    Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
  • « Previous Page
  • 1
  • …
  • 941
  • 942
  • 943
  • 944
  • 945
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology